At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed May 8, 2026 at 17:20 ET
FDA approved label expansion for VYVGART and VYVGART Hytrulo to treat all serotypes of generalized myasthenia gravis (gMG), including anti-MuSK, anti-LRP4, and triple-seronegative patients. The expansion is based on positive Phase 3 ADAPT SERON data and increases the addressable gMG patient population by approximately 20%.
- FDA approved label expansion for VYVGART and VYVGART Hytrulo to cover all gMG serotypes (anti-AChR, anti-MuSK, anti-LRP4, triple seronegative).
- Approval based on Phase 3 ADAPT SERON study (n=119) showing significant improvement in MG-ADL score at week 4 (p=0.0068).
- Expands addressable gMG patients by ~20% (non-AChR-Ab positive patients).
- VYVGART now has the broadest MG label to date.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access